Advertisement

Surgery Today

, Volume 48, Issue 6, pp 618–624 | Cite as

National survey of de novo malignancy after solid organ transplantation in Japan

  • Takuro MiyazakiEmail author
  • Shuntaro Sato
  • Takashi Kondo
  • Mamoru Kusaka
  • Mitsukazu Gotoh
  • Yoshikatsu Saiki
  • Minoru Ono
  • Norihiro Kokudo
  • Shin Enosawa
  • Shigeru Satoh
  • Etsuko Soeda
  • Hiroyuki Furukawa
  • Eiji Kobayashi
  • Takeshi Nagayasu
Original Article

Abstract

Purpose

In Japan, there have been no national surveys on the incidence of de novo malignancy after solid organ transplantation, which is one of the leading causes of death in transplant recipients.

Methods

A questionnaire was distributed to institutions that perform solid organ transplantation in Japan, and clinical information was collected from patients who underwent transplantation between 2001 and 2010 and who exhibited de novo malignancies.

Results

Nine thousand two hundred ten solid organ transplants (kidney, 49.9%; liver, 45.9%; heart, 0.9%; lung, 1.2%; pancreas, 1.9%; small intestine, 0.2%) were performed. Four hundred seventy-nine (5.2%) cases of de novo malignancy were identified. The transplanted organs of the patients included the kidney (n = 479, 54.8%), liver (n = 186, 38.8%), heart (n = 5, 0.1%), lung (n = 18, 3.8%), pancreas (n = 9, 1.9%), and small intestine (n = 1, 0.02%). The most common malignancies were post-transplant lymphoproliferative disorder (n = 87) and cancers of the kidney (n = 43), stomach (n = 41), large intestine (n = 41), and lung (n = 36).

Conclusions

This is the first national survey of the incidence of de novo malignancy in Japan. Further study is required to identify the risk of de novo malignancy in organ transplant recipients in comparison to the general population, namely the standardized incidence ratio.

Keywords

De novo malignancy Solid organ transplantation Immunosuppression Post-transplant lymphoproliferative disorder Cancer screening 

Notes

Acknowledgements

The authors would like to thank the members of the academic committee of the Japanese Society for Transplantation and the medical doctors who cooperated with this survey.

Compliance with ethical standards

Conflict of interest

Minoru Ono received research funding from Astellas Pharma. Inc.; Norihito Kokudo received research funding from TAIHO Pharma.

References

  1. 1.
    Sherston SN, Carrolll RP, Harden PH, Wood KJ. Predictors of cancer risk in the long-term solid-organ transplant recipient. Transplantation. 2014;97:605.CrossRefPubMedGoogle Scholar
  2. 2.
    Albugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transplant Rev. 2014;28:76.CrossRefGoogle Scholar
  3. 3.
    Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, et al. New concepts and best practice for management of pre- and post-transplantation cancer. Transplant Rev. 2012;26:261.CrossRefGoogle Scholar
  4. 4.
    Herman M, Weinstein T, Korzets A, Chaqnac A, Ori Y, Zevin D, et al. Effect of cyclosporine A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med. 2001;137:14.CrossRefPubMedGoogle Scholar
  5. 5.
    Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sampaio MS, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients; an analysis of the U.S. national transplant database. Transplantation. 2012;94:990.CrossRefPubMedGoogle Scholar
  7. 7.
    Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010;10:1889.CrossRefPubMedGoogle Scholar
  8. 8.
    Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant. 2012;13:174.CrossRefPubMedGoogle Scholar
  9. 9.
    Suzuki S, Tanaka K, Ohsaka Y, Nakai I, Yasumura T, Ohmori Y, et al. Development of de novo malignancies following renal transplantation: a single-center study. Transplant Proc. 1994;26:938.PubMedGoogle Scholar
  10. 10.
    Kato T, Kakuta Y, Abe T, Yamanaka K, Imamura R, Okumi M, et al. The benefits of cancer screening in kidney transplant recipients: a single-center experience. Cancer Med. 2016;5:153.CrossRefPubMedGoogle Scholar
  11. 11.
    Imao T, Ichimaru N, Takahara S, Kokado Y, Okumi M, Imamura R, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer. 2007;109:2109.CrossRefPubMedGoogle Scholar
  12. 12.
    Kaneko K, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, et al. De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study. Transplantation. 2013;95:1142.CrossRefPubMedGoogle Scholar
  13. 13.
    Sato M, Okada Y, Oto T, Minami M, Shiraishi T, Nagayasu T, et al. Registry of the Japanese Society of lung and heart-lung transplantation: official Japanese lung transplantation report, 2014. Gen Thorac Cardiovasc Surg. 2014;62:594.CrossRefPubMedGoogle Scholar
  14. 14.
    Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. http://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence, the last data update on December 15, 2015, Accessed date 4th Jan 2016.
  15. 15.
    Breslow NE, Day N. The design and analysis of cohort studies. Vol 2 Lyon: International agency for research on cancer; 1987.Google Scholar
  16. 16.
    Miyazaki T, Oto T, Okumura M, Date H, Shiraishi T, Okada Y, et al. De novo malignancy after lung transplantation in Japan. Gen Thorac Cardiovasc Surg. 2016;64:543.CrossRefPubMedGoogle Scholar
  17. 17.
    Tomimaru Y, Ito T, Marubashi S, Kawamoto K, Tomokuni A, AsakokaT, et al. De novo malignancy after pancreas transplantation in Japan. Transplant Proc. 2015;47:742.CrossRefPubMedGoogle Scholar
  18. 18.
    Acuna SA, Fernandes KA, Daly C, Hicks LK, Sutradhar R, Kim SJ, et al. Cancer Mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncol. 2016;2:463.CrossRefPubMedGoogle Scholar
  19. 19.
    Olland AM, Falcoz PE, Santelmo N, Kessler R, Massard G. Primary lung cancer in lung transplant recipients. Ann Thorac Surg. 2014;98:362.CrossRefPubMedGoogle Scholar
  20. 20.
    Kobayashi S, Soyama A, Takatsuki M, Hidaka M, Adachi T, Kitasato A, et al. Relationship between immune function recovery and infectious complications in patients following living donor liver transplantation. Hepatol Res. 2016;46:908.CrossRefPubMedGoogle Scholar
  21. 21.
    Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int. 2007;20(3):207.CrossRefPubMedGoogle Scholar
  22. 22.
    Bhat M, Watt KD. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? Clin Transplant. 2015;29:654.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Takuro Miyazaki
    • 1
    Email author
  • Shuntaro Sato
    • 2
  • Takashi Kondo
    • 3
  • Mamoru Kusaka
    • 4
  • Mitsukazu Gotoh
    • 5
  • Yoshikatsu Saiki
    • 6
  • Minoru Ono
    • 7
  • Norihiro Kokudo
    • 8
  • Shin Enosawa
    • 9
  • Shigeru Satoh
    • 10
  • Etsuko Soeda
    • 11
  • Hiroyuki Furukawa
    • 12
  • Eiji Kobayashi
    • 13
  • Takeshi Nagayasu
    • 1
  1. 1.Department of Surgical OncologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Clinical Research CenterNagasaki University HospitalNagasakiJapan
  3. 3.Tohoku Pharmaceutical University HospitalSendaiJapan
  4. 4.Department of UrologyFujita Health University School of MedicineToyoakeJapan
  5. 5.Osaka General Medical Center, PresidentOsakaJapan
  6. 6.Department of Cardiovascular SurgeryTohoku University HospitalSendaiJapan
  7. 7.Department of Cardiac SurgeryThe University of Tokyo HospitalTokyoJapan
  8. 8.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of MedicineThe University of TokyoTokyoJapan
  9. 9.Division for Advanced Medical SciencesNational Center for Child Health and DevelopmentTokyoJapan
  10. 10.Center for Kidney Disease and TransplantationAkita University HospitalAkitaJapan
  11. 11.Faculty of Nursing and Medical CareKeio UniversityFujisawaJapan
  12. 12.Department of Gastroenterologic and General SurgeryAsahikawa Medical UniversityAsahikawaJapan
  13. 13.Department of Organ FabricationKeio University School of MedicineTokyoJapan

Personalised recommendations